iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Breakthrough Antibiotic Exblifeb Receives Nod from European Medicines Agency

1 Feb 2024 , 11:11 AM

The antibiotic Exblifeb, developed by Chennai-based Orchid Pharma, is a major breakthrough as it contains Enmetazobactam, the first entirely Indian-developed beta lactamase inhibitor.

This ground-breaking medication became the first to achieve this stage of clinical development when it was recommended for marketing authorization by the European Medicines Agency (EMA) recently. The medication was invented in India.

‘Exblifeb’, created to combat the worldwide problem of Anti-Microbial Resistance (AMR), shows exceptional effectiveness in treating pneumonia, bacteremia, and complex urinary tract infections (cUTI) brought on by organisms that produce Extended Spectrum Beta-lactamases.

‘Exblifeb’ performed better in clinical studies than Piperacillin + Tazobactam, the standard medication. It is marketed as a strong, reasonably priced, and carbapenem-sparing medication that provides a workable way to combat the growing AMR epidemic.

This accomplishment not only establishes ‘Exblifeb’ as a leader in the fight against AMR, but it also emphasises how urgently practical solutions are needed. 

Orchid created enmetazobactam in India, and Allecra Therapeutics, a company based in the US, was granted an outlicense to continue developing it.

For feedback and suggestions, write to us at editorial@iifl.com

Orchid Pharma | LinkedIn

Related Tags

  • European Medicines Agency
  • Orchid Pharma
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.